// App-Quantinova.ai

9527 : Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

Researchers

Presenter

  • Jessica Cecile Hassel

Principal Investigators

  • Jean-Francois Baurain

  • Marcus O. Butler

  • Max Schlaak

  • Ryan Sullivan

  • Sebastian Ochsenreither

  • Reinhard Dummer

  • John M. Kirkwood

  • Anthony M. Joshua

  • Joseph J. Sacco

  • Alexander Noor Shoushtari

  • Marlana Orloff

  • Richard D. Carvajal

  • Omid Hamid

  • Shaad Essa Abdullah

  • Chris Holland

  • Howard Goodall

  • Paul Nathan

  • Sophie Piperno-Neumann

Medical Centers

  • Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • Institut Roi Albert II, Cliniques universitaires St-Luc, UCL, Brussels, Belgium

  • Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

  • University Hospital, Department of Dermatology and Allergy, LMU Munich, Munich, Germany

  • Massachusetts General Hospital, Boston, MA

  • Charite Comprehensive Cancer Center, Berlin, Germany

  • Skin Cancer Center, University Hospital of Zürich, Zürich, Switzerland

  • University of Pittsburgh Medical Center, Pittsburgh, PA, Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia

  • Clatterbridge Cancer Centre, Merseyside, United Kingdom

  • Memorial Sloan Kettering Cancer Center, New York, NY, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, The Angeles Clinic and Research Institute, Los Angeles, CA

  • Immunocore, Ltd, Abingdon, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Institut Curie, Paris Cedex, France

Locations

  • Germany

  • Poland

  • Belgium

  • Canada

  • Switzerland

  • Australia

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Uveal melanoma

Biomarkers

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • GP100

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT03070392

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved